Reviewer’s report

Title: Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice

Version: 0 Date: 21 Apr 2019

Reviewer: Yu-Chen Liu

Reviewer’s report:

The authors suggested that Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice and enhance the efficacy of doxorubicin.

The research work on this manuscript was done very well. I have some questions or suggestions:

1. The authors can add a picture to describe the core ideas and key conclusions of this manuscript. For example: Smac mimetics can cooperate with TNFα secreted by tumor-Associated myeloid cells to kill osteosarcoma cells in vivo.

2. The author also mentioned: co-treatments were also more toxic. How to avoid this problem and further improve the safety of biological treatment?

3. I want to ask whether the authors can consider to prove that the addition of TNFα on the basis of the combination of the two drugs can effectively inhibit the development of the tumors in vivo.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Acceptable

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal